8-KEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 26, 2012)

Filed April 26, 2012For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on April 26, 2012, to announce its financial results for the first quarter of 2012. This filing serves as a notification to investors regarding the company's performance and provides access to the detailed financial information. The press release and supplemental information, included as exhibits, contain the core data concerning the company's operational and financial standing during the period. Investors should review the furnished exhibits, specifically the press release (Exhibit 99.1) and supplemental website information (Exhibit 99.2), to understand BMY's first-quarter 2012 financial results. These documents are crucial for assessing the company's profitability, revenue streams, and overall financial health as reported by management.

Key Highlights

  • 1BMY filed an 8-K on April 26, 2012, to report its Q1 2012 financial results.
  • 2The filing includes a press release dated April 26, 2012, detailing the financial outcomes.
  • 3Supplemental financial information was also posted on the company's website and is incorporated by reference.
  • 4Investors can access specific Q1 2012 financial data through the provided exhibits.
  • 5The report focuses on the company's results of operations and financial condition.
  • 6No specific operational or financial figures are detailed within the 8-K itself, but it directs investors to the relevant disclosures.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and provide access to Bristol-Myers Squibb Company's financial results for the first quarter of 2012.

The detailed financial results are primarily found in the press release dated April 26, 2012 (Exhibit 99.1) and in certain supplemental information posted on the company's website (Exhibit 99.2), both of which are furnished as part of this 8-K filing.

No, the 8-K filing itself, as presented here, does not contain the specific financial numbers. It serves as a notification and directs investors to the attached exhibits (press release and supplemental information) which contain the detailed financial data for the first quarter of 2012.

Exhibit 99.2 refers to additional supplemental information related to the Q1 2012 financial results that was posted on Bristol-Myers Squibb's website. This likely provides further details or context beyond what is included in the main press release.